Second-Line Therapy for Metastatic Renal Cell Carcinoma: Making Strategic Choices
Originally presented at HOPA's 13th Annual Conference, March 2017
This session will explore new therapeutic options for the second-line treatment of metastatic renal cell carcinoma. As treatment options have expanded, the preferred second-line agent is being debated. Evidence for targeted therapies and immunotherapy in the second-line setting will be reviewed, with discussion of the advantages and disadvantages of therapy. This session will help the oncology pharmacist determine a strategy for selecting and recommending a second-line treatment option for a patient with metastatic renal cell carcinoma.
- Identify controversies surrounding second-line therapy for metastatic renal cell carcinoma.
- Evaluate the evidence for use of targeted therapy and immunotherapy for second-line therapy.
- Apply evidence to selected second-line therapy based on patient specific factors.
Jocelyn Mohs, PharmD BCOP
Jocelyn Mohs is the oncology/specialty clinical pharmacist at the St. Cloud VA Health Care System in St. Cloud, MN. She completed her PharmD degree in 2008 at Creighton University in Omaha, NE, and completed a PGY-1 pharmacy practice residency at the Minneapolis VA Medical Center in Minneapolis, MN, and a PGY-2 oncology specialty residency at the University of Minnesota Medical Center, Fairview in Minneapolis and Maple Grove. She became board certified in oncology pharmacy in 2011.
Anne Spengler, PharmD BCOP
Anne Spengler completed her PharmD degree at the University of Washington School of Pharmacy, a PGY-1 residency in acute care at the University of California–San Diego, and a PGY-2 residency in oncology at UW Medicine/Seattle Cancer Care Alliance. She currently practices as a clinical oncology pharmacist at UW Medicine/Seattle Cancer Care Alliance and is a clinical instructor at the University of Washington School of Pharmacy.
Rebecca Greene, PharmD BCOP
Rebecca Greene received her PharmD degree from the University of North Carolina. She completed a pharmacy practice residency with the University of North Carolina Hospitals and an oncology pharmacy residency with the South Texas Veterans Healthcare System, Audie Murphy VA Hospital. She was a clinical pharmacy specialist at Grady Health System for 1 year before returning to the South Texas Veterans Healthcare System, where she spent 8 years as clinical pharmacy specialist and residency program director for the PGY-2 oncology pharmacy residency. Since 2012 she has been pharmacy program manager for oncology at the Orlando VA Medical Center.
Patient Management & Therapeutics
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 29, 2020.
This activity has been approved for .125 CEUs
This course is also included as part of the Best of AC2017 Bundle product.
Release Date: August 31, 2017
Expiration Date: March 29, 2020